We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Oxford Gene Technology Appoints Research and Development Director

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Gene Technology Appoints Research and Development Director"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Oxford Gene Technology has announced the appointment of Dr John Anson as Research and Development Director.

John joins OGT after 16 years at Amersham Biosciences/GE Healthcare where he held positions as Head of Product Development, Lead Discovery, Cardiff; Vice President for Pharmacogenomics; Vice President for Business Development and Programme Manager.

John brings to OGT a wide experience of product development for the life science market, having led teams responsible for the launch of several industry-leading products, including the IN Cell analyser for automated cell-based assays and LEADseeker for in vitro drug screening.

Prior to Amersham Biosciences, John carried out Post Doctorate research at PHLS Centre for Applied Microbiology and Research, Porton Down, and holds a PhD in Bacterial Genetics from Cranfield University and a BSc (Hons) in Microbiology from the University of Kent.

"I am looking forward to joining OGT and working with its scientists to develop products and services for commercialisation into the life science and molecular medicine markets," said John.

Dr Mike Evans, OGT's Chief Executive, said, "I am delighted to welcome John to OGT."

"With his track record and experience in research, product development and management of collaborations, John will make a major contribution to OGT's development of products and services for the life science and molecular medicine markets."